Q2 EPS Estimates for Kura Oncology Lowered by HC Wainwright

Kura Oncology, Inc. (NASDAQ:KURA) – Research analysts at HC Wainwright dropped their Q2 2026 earnings per share estimates for Kura Oncology in a report issued on Wednesday, May 13th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.89) for the quarter, down from their prior estimate of ($0.80). The consensus estimate for Kura Oncology’s current full-year earnings is ($3.36) per share. HC Wainwright also issued estimates for Kura Oncology’s Q3 2026 earnings at ($0.92) EPS, Q4 2026 earnings at ($0.94) EPS, FY2026 earnings at ($3.57) EPS, FY2027 earnings at ($2.70) EPS, FY2028 earnings at ($2.34) EPS and FY2029 earnings at ($2.16) EPS.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The business had revenue of $18.27 million during the quarter, compared to analysts’ expectations of $25.97 million.

A number of other equities analysts have also recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a report on Tuesday, April 21st. Mizuho reduced their price target on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, March 24th. Wall Street Zen cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Monday, March 2nd. Zacks Research upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Thursday, February 26th. Finally, Wedbush reduced their price target on Kura Oncology from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, March 6th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.38.

Kura Oncology Trading Up 2.7%

Kura Oncology stock opened at $9.74 on Friday. Kura Oncology has a 52 week low of $5.45 and a 52 week high of $12.49. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.05 and a current ratio of 6.15. The stock has a market capitalization of $864.62 million, a P/E ratio of -2.91 and a beta of 0.32. The stock has a 50-day simple moving average of $8.88 and a 200 day simple moving average of $9.47.

Institutional Investors Weigh In On Kura Oncology

Institutional investors have recently made changes to their positions in the company. IFP Advisors Inc boosted its holdings in shares of Kura Oncology by 115.3% during the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after acquiring an additional 1,284 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Kura Oncology by 392.8% during the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after acquiring an additional 3,072 shares during the period. Allworth Financial LP boosted its holdings in shares of Kura Oncology by 59.9% during the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after acquiring an additional 1,553 shares during the period. PNC Financial Services Group Inc. boosted its holdings in shares of Kura Oncology by 127.2% during the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after acquiring an additional 3,769 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Kura Oncology by 471.3% during the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after acquiring an additional 9,958 shares during the period.

Key Stories Impacting Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: Kura Oncology reported strong early momentum for KOMZIFTI, including $5.8 million in first full-launch-quarter sales, and reiterated a 2028 timeline for first top-line KOMET-017 Phase III results, underscoring both near-term commercial uptake and long-term pipeline potential. Article Title
• Positive Sentiment: Barclays initiated/maintained a bullish stance with a Buy rating, and broader analyst coverage still shows a Moderate Buy consensus, which can help sentiment around KURA. Article Title
• Neutral Sentiment: The company’s Q1 2026 earnings call emphasized launch execution and development progress, but the most recent transcript headlines did not add a major new catalyst beyond the KOMZIFTI update. Article Title
• Neutral Sentiment: Kura presented at the Bank of America Global Healthcare Conference, which keeps the stock visible to investors but is not, by itself, a fundamental change in outlook. Article Title
• Negative Sentiment: HC Wainwright trimmed earnings estimates across multiple periods, including FY2026 through FY2029, signaling a more cautious near- and long-term profit outlook for Kura Oncology. Article Title

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.